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Abstract  
Background: Preclinical studies have identified certain probiotics as psychobiotics - live 
microorganisms with a potential mental health benefit. Lactobacillus rhamnosus (JB-1) 
has been shown to reduce stress-related behaviour, corticosterone release and alter 
central expression of GABA receptors in an anxious mouse strain. However, it is 
unclear if this single putative psychobiotic strain has psychotropic activity in humans. 
Consequently, we aimed to examine if these promising preclinical findings could be 
translated to healthy human volunteers. 
Objectives: To determine the impact of L. rhamnosus on stress-related behaviours, 
physiology, inflammatory response, cognitive performance and brain activity patterns 
in healthy male participants. 
Methods: An 8 week, randomized, placebo-controlled, cross-over design was 
employed. Twenty-nine healthy male volunteers participated. Participants completed 
self-report stress measures, cognitive assessments and resting 
electroencephalography (EEG). Plasma IL10, IL1β, IL6, IL8 and TNFα levels and whole 
blood Toll-like 4 (TLR-4) agonist-induced cytokine release were determined by 
multiplex ELISA. Salivary cortisol was determined by ELISA and subjective stress 
measures were assessed before, during and after a socially evaluated cold pressor test 
(SECPT).  
Results: There was no overall effect of probiotic treatment on measures of mood, 
anxiety, stress or sleep quality and no significant effect of probiotic over placebo on 
subjective stress measures, or the HPA response to the SECPT. Visuospatial memory 
performance, attention switching, rapid visual information processing, emotion 
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recognition and associated EEG measures did not show improvement over placebo. No 
significant anti-inflammatory effects were seen as assessed by basal and stimulated 
cytokine levels. 
Conclusions: L. rhamnosus was not superior to placebo in modifying stress-related 
measures, HPA response, inflammation or cognitive performance in healthy male 
participants. These findings highlight the challenges associated with moving promising 
preclinical studies, conducted in an anxious mouse strain, to healthy human 
participants. Future interventional studies investigating the effect of this psychobiotic 
in populations with stress-related disorders are required. 
Keywords: Psychobiotic, brain-gut axis, stress, cognition, memory, EEG. 
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Introduction 
An abundance of preclinical studies have shown that probiotics acting via the brain-
gut-axis can affect brain development, function and behaviour (Bercik et al., 2011a; 
Buffington et al., 2016; Cryan and Dinan, 2015; Desbonnet et al., 2014; Desbonnet et 
al., 2010; Hsiao et al., 2013). This has prompted a growing interest in the possibility of 
targeting the gut microbiota to beneficially impact human brain function and 
behaviour. Psychobiotics have been defined as bacteria that ingested in adequate 
amounts produce a positive mental health benefit (Dinan et al., 2013).  
 
Considering the potential impact of putative psychobiotics upon central nervous 
system processes, especially stress, mood, anxiety and cognition (Cryan and Dinan, 
2012; Dinan et al., 2015), the prospect of targeting the gut microbiota as a potential 
modifiable risk factor for stress-related disorders is appealing (Kelly et al., 2015). 
Preclinical research has indicated that chronic probiotic administration can reduce 
anxiety-like and depressive-like behaviour, and can normalise associated physiological 
outputs such as corticosterone, noradrenaline, brain-derived neurotrophic factor 
(BDNF) and immune function (Bercik et al., 2011b; Bravo et al., 2011; Desbonnet et al., 
2010; Janik et al., 2016; Messaoudi et al., 2011). There is a growing appreciation of the 
need to translate this promising preclinical work to the clinic while at the same time  
recognising the challenges inherent in this process (Kelly et al., 2016b).  
 
To date, there are indications from a number of sources that highlight the 
opportunities in this regard, for example, probiotic use in irritable bowel syndrome 
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(IBS) (O’Mahony et al., 2005; Whorwell et al., 2006), a stress-related brain-gut axis 
disorder associated with high rates of psychopathology (Whitehead et al., 2002) as 
well as altered hypothalamic-pituitary-adrenal (HPA) axis activity (Kennedy et al., 
2014b) and cognition (Kennedy et al., 2015; Kennedy et al., 2014a). A number of 
proof-of-principle studies in healthy human volunteers have demonstrated that multi-
strain probiotics, fermented drinks containing probiotics, or prebiotics, can alter 
resting brain activity, cognitive performance, baseline physiological stress outputs and 
self-reported psychological variables (Benton et al., 2007; Chung et al., 2014; 
Messaoudi et al., 2011; Mohammadi et al., 2015b; Schmidt et al., 2015; Steenbergen 
et al., 2015; Tillisch et al., 2013). More recently, Bifidobacterium longum 1714, 
selected based on pre-clinical evidence (Savignac et al., 2014; Savignac et al., 2015), 
was shown to reduce stress levels and to produce a neurocognitive profile associated 
with enhanced memory in healthy volunteers (Allen et al., 2016).  
 
By utilizing a well-validated preclinical screening platform, developed to inform 
efficient selection of prospective psychobiotic strains, we identified L. rhamnosus (JB-
1). In these studies, which were carried out in the stress-sensitive BALB/c mice, 
ingestion of the JB-1 strain reduced anxiety in the elevated plus maze and despair-like 
behaviour in the forced swim test. Moreover, there was enhanced learning in a fear 
conditioning paradigm and reduced stress-induced corticosterone levels. At a brain 
level there were marked alterations in central GABAA and GABAB receptor levels 
(Bravo et al., 2011). Furthermore, a magnetic resonance spectroscopy study, also 
conducted in BALB/c mice showed that treatment with the JB-1 strain significantly 
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elevated central GABA levels by 25% after four weeks of treatment (Janik et al., 2016). 
In addition, L. rhamnosus treatment modulates the immune system (Forsythe et al., 
2012; Karimi et al., 2009; Kozakova et al., 2016; Ma et al., 2004), intestinal motility 
(Wang et al., 2010), gut barrier function (Patel et al., 2012; Wang et al., 2012) and 
enteric nervous system (Kamiya et al., 2006; Ma et al., 2009). Taken together, these 
preclinical studies identify L. rhamnosus as a candidate psychobiotic with the one of 
the most comprehensive behavioural, physiological and neurobiological profiles. 
 
We employed a randomized, placebo-controlled, cross-over, repeated measures 
design to examine the effects of the JB-1 strain compared to placebo on the 
psychobiological response to an acute, controlled stressor (Schwabe et al., 2008; 
Schwabe and Wolf, 2010) and assessed cognitive performance on tests assessing 
memory, sustained attention, social cognition and emotional processing. In addition, 
we measured the immune response to this candidate psychobiotic by measuring a 
panel of cytokines. Finally, to ascertain if the JB-1 strain effected brain activity 
patterns, we assessed brain activity in frontal, parietal and central regions using EEG 
following 4-week supplementation with the JB-1 strain in comparison to placebo, as 
these regions have been associated with memory and sustained attention (Coull et al., 
1996; Hales et al., 2009) and are sensitive to anxiolytics (Fukami et al., 2010) and 
psychobiotics (Allen et al., 2016).  
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Methods  
Subjects 
Approval of the study protocol was granted by the Cork University Hospital ethics 
committee (Protocol Number: APC057) and conducted in accordance with the ICH 
Guidelines on Good Clinical Practice, and the Declaration of Helsinki. Written informed 
consent was obtained from all subjects before any study procedures were conducted.  
 
Participants were aged between 20 and 33 years of age. Inclusion criteria were as 
follows: aged between 18 - 40 years, able to speak English, in good health as 
determined by the investigator. Male participants were selected to avoid the influence 
of the menstrual cycle, which can impact upon cortisol output and other readouts and 
all preclinical studies with this bacteria to date have focused on male animals (Bravo et 
al., 2011). Exclusion criteria were as follows: having a significant acute or chronic 
illness, following a diet or taking a medication that would interfere with the objectives 
of the study, pose a safety risk or confound the interpretation of the study results; to 
include, probiotics, antibiotics, antipsychotics, anxiolytics, laxatives, enemas, anti-
coagulants and over-the counter non-steroidal anti-inflammatorys (NSAIDS), 
antidepressants or any other psychotropic medication. Evidence of immunodeficiency, 
bleeding disorder or coagulopathy, colour blindness, dyslexia or dyscalculia, or 
receiving any treatment involving experimental drugs.  
 
Design 
A repeated measures cross-over design was employed. Participants were screened at 
an initial visit for psychiatric disorder using the MINI International Neuropsychiatric 
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Interview (MINI) (Sheehan et al., 1998) and demographic and baseline psychological 
information was collected. Following screening, participants completed neurocognitive 
visits and acute stress visits utilizing the socially evaluated cold pressor test (SECPT) at 
baseline, at 4 weeks and at 8 weeks. See Supplementary Figure S1 for the study 
design. Participants were administered placebo capsules for four weeks or L. 
rhamnosus capsules for four weeks and they then switched to the alternative 
treatment. See Table 1 for detailed participant characteristics.  
 
Materials  
Both active and placebo capsules contained corn starch, magnesium stearate and 
silicon dioxide. The count for L. rhamnosus (JB-1) in the active capsules was 1x10
9 
colony-forming units (CFU). Participants were instructed to take one capsule each 
morning.  
 
Tests from the CANTAB Battery  
Tests from the Cambridge Neuropsychological Test Automated Battery (CANTAB) were 
presented on a touch-screen monitor, Sahara i440D Slate Tablet PC (Sand Dune 
Ventures, Tablet Kiosk) running CANTABeclipse™ software (Cambridge, UK) as 
previously described (Allen et al., 2016; Kennedy et al., 2014a). The researcher 
provided verbal instructions to participants from a standardised script, and had full 
control of a keyboard used to start, pause or abort each test. As a test battery of 
multiple cognitive tests was employed, test order was counterbalanced, using a Latin 
square design, to avoid effects of fatigue for tests completed later in the session. The 
test battery lasted approximately 45 minutes in total. Participants were assessed on 
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the following tests: Motor Screening Test (MOT), Paired Associates Learning (PAL), 
Attention Switching Task (AST), Rapid visual information processing (RVP), Emotion 
Recognition Task (ERT) and Emotional Stroop. See Supplementary Methods section 
for details of CANTAB tests.  
 
Acute Stress Procedure  
We employed the socially evaluated cold pressor test (SECPT) (Schwabe et al., 2008) as 
a combined psychological and physiological stressor procedure, which has been shown 
not to induce HPA axis habituation across repeated exposures (Minkley et al., 2014). 
Participants were required to avoid alcohol for 24 hours prior to the visit, as well as 
caffeinated beverages on the day of the stress procedure and strenuous exercise from 
2pm the day before, and to fast for 2 hours prior to testing. See Supplementary 
Methods section for details of SECPT procedure.   
 
Neurocognitive assessment 
Prior to EEG testing participants were asked to refrain from caffeine on the morning of 
their experimental session, to remove any piercings and avoid wearing hair gel. All EEG 
measurements were made using a Neuroscan®, SynAmps 2 Amplifier and Neuroscan 
4.3.1 acquisition software. EEG was recorded at a sampling rate of 1,000Hz. Scalp 
electrodes were attached at midline positions Fz, Pz, Cz, and F1, F2, F3, F4, F5, F6, F7, 
F8, according to the international 10/20 system, as well as mastoid electrodes and a 
reference electrode on the nose. Vertical eye movements were detected using 
electrodes attached above and below the orbit of the left eye, simultaneously 
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horizontal eye movements were monitored by electrodes at the right and left outer 
canthi. EEG recordings were made using Neuroscan® Quick-Cap (containing AgCl 
sintered electrodes and Neuroscan Quick-Cell technology) therefore ensuring reduced 
impedance levels for optimized recordings at each electrode. Following a resting EEG 
recording, the cognitive tasks were completed (see Cognitive tasks).  
 
Resting EEG 
EEG measures of absolute power in the delta (2-4Hz), theta1 (4-6Hz), theta2 (6-8 Hz) 
alpha1 (8-10Hz), alpha2 (10-12Hz), beta (15-30Hz) frequency bands were taken for five 
minutes with eyes closed. Participants were requested to relax and sit still with their 
eyes closed while resting EEG was recorded.  
 
EEG analysis  
The EEG signal was down sampled from 1000Hz to 256Hz with an antialiasing filter set 
at 128Hz. The filtered EEG signal was segmented into 1s windows without overlap. 
Curve length, root mean squared amplitude, Hjorth parameters (activity, mobility, 
complexity) (Hjorth, 1970), zero crossings (raw epoch, first and second derivative), 
autoregressive modelling error (model order 1-9), nonlinear energy, variance (first and 
second derivative), entropy (Shannon entropy, spectral entropy, singular value 
decomposition entropy), Fisher information, and wavelet energy (Daubechy 4) were 
calculated using MATLAB. EEG measures of absolute power were extracted in the delta 
(2-4Hz), theta1 (4-6Hz), theta2 (6-8 Hz) alpha1 (8-10Hz), alpha2 (10-12Hz), beta (15-
30Hz) frequency bands. 
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Sample analysis 
Cortisol sampling & analysis 
Salivettes were centrifuged at 1000 g for 5 min and aliquoted and stored at -80
o
C until 
analysis. Cortisol concentrations were determined using the Cortisol Enzyme 
Immunoassay Kit as per manufacturers’ instruction (Enzo®, Life Sciences). Assay 
detection limit was 0.16 nmol/L. Inter and intra-assay % C.Vs were 11.24% and 8.2% 
respectively. 
 
Cytokine sampling & analysis 
10ml of whole blood was collected in an EDTA tube. Samples were centrifuged at 1000 
g for 15 minutes and then aliquoted and stored at -80
o
C until analysis. Plasma levels of 
IL1β, IL6, IL8, IL10 and TNFα were assayed in duplicate using high sensitivity 
commercially available electrochemiluminescence MULTI-SPOT® Meso Scale Discovery 
kits (MSD, Rockville, MD, 75USA) as per manufacturer’s instructions. The median lower 
limits of detection for each cytokine are; IL-1β; 0.04 pg/ml, IL-6; 0.06 pg/ml, IL-8; 0.04 
pg/ml, IL-10; 0.03 pg/ml, TNF-α 0.04 pg/ml.  
 
TLR-4 cytokine release 
TLR cytokine release was determined as previously described (McKernan et al., 2011). 
Whole blood was collected in lithium heparin tubes and diluted 1:10 with Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Calf Serum (FCS) and 
5% penicillin streptomycin. Each blood sample was cultured with and without the TLR-
4 receptor ligand - lipopolysaccharide (LPS), from the Human TLR agonist kit 
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(InvivoGen, San Diego, CA, USA) for 24 hours. After the 24 hour culture period the 
supernatant from both untreated and stimulated cells was aspirated and stored at -
80°C. Levels of IL1β, IL6, IL8, I-10 and TNFα were assayed in duplicate using high 
sensitivity commercially available electrochemiluminescence MULTI-SPOT® Meso Scale 
Discovery kits (MSD, Rockville, MD, 75USA) as per manufacturer’s instructions. 
 
Statistical analysis 
With a power of 0.8 for a one-way ANOVA, a minimum sample size of 20 was required 
to demonstrate an effect sized f = 0.3 at alpha = 0.05 (Allen et al., 2016; Buchner et al., 
1997). Data were analysed using SPSS 21. Repeated measures ANOVA and pairwise t-
tests using post-hoc Fisher's least significant difference (LSD) were used to examine 
differences between conditions, and non-parametric equivalents (Friedman and 
Wilcoxon respectively) were used where parametric assumptions were violated. Areas 
under the curve with respect to ground (AUCg) were also calculated (Pruessner et al., 
2003), and analysed in the same manner.  
 
Results 
 
Subjective stress measures 
A repeated measures ANOVA with a Greenhouse-Geisser correction determined that 
there was no overall effect of treatment phase on the Beck Depression Inventory (p = 
0.75), the Beck Anxiety Inventory (p = 0.95), the Perceived Stress Scale (p = 0.053), the 
State Anxiety Inventory (p = 0.09), the Trait Anxiety Inventory (p = 0.72), the Symptom 
Checklist-90 (p = 0.87) or the Pittsburgh sleep quality index (p = 0.07). In the coping 
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checklist, there was a reduction in wishful thinking (p = 0.03) in both the placebo (p = 
0.04) and probiotic phase (p = 0.02), see (Figure 1). For pairwise comparisons see 
Supplementary Table 1.  
 
Acute Stress response to the SECPT 
There was no overall effect of treatment phase on subjective stress measures pre or 
post the SECPT (see Figure 2A-H), and no significant overall effect of probiotic over 
placebo in HPA response to the SECPT (Figure 2I-J). See Supplementary Table 2 for 
pairwise comparisons.   
 
Immune response 
There was no overall treatment effect on the concentrations of IL10 (p = 0.32), IL1β (p 
= 0.23), IL6 (p = 0.13) or IL8 (p = 0.16) (Figure 3A-D). The concentration of TNFα 
increased from baseline during the placebo phase (p = 0.02), but there was no 
significant change in baseline versus probiotic (p = 0.08) or placebo versus probiotic (p 
= 0.18) (Figure 3E). There was no overall treatment effect on the IL1β:IL10 (p = 0.99), 
IL6:IL10 (p = 0.12), IL8:IL10 (p = 0.97), or TNFα:IL10 (p = 0.99) ratios (Figure 3F-I).  
 
TLR-4 cytokine release 
In the TLR-4 stimulated cytokines, there was an increase in the level of IL1β (p = 0.02) 
(Figure 3J) and TNFα (p = 0.01) (Figure 3K) during the placebo phase compared to 
baseline (p = 0.01) but no effect of probiotic (p = 0.03). There was no effect of either 
treatment phase on TLR-4 stimulated IL10 (p = 0.12), IL6 (p = 0.22) or IL8 (p = 0.25) 
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cytokine release (Figure 3L-M).  See Supplementary Table 3 for pairwise comparisons 
of inflammatory Measures.  
 
Cognitive Measures  
Paired Associates Learning (PAL) 
There was no overall treatment effect on the total errors made (p = 0.06) (Figure 4A), 
however at the 8 shape stage (Figure 4B), there was a significant reduction in errors 
from baseline in the placebo (p = 0.04) and probiotic phases (p = 0.04), but no 
significant difference between the placebo and probiotic. There was no significant 
difference in the mean trials to success (p = 0.13) (Figure 4C).  
 
Attention Switching Task (AST) 
There was an increase in the correct response in the placebo (p = 0.03) (Figure 4D) and 
probiotic treatment phases (p = 0.01) compared to baseline, and a decrease in the 
reaction time to correct response (Figure 4E) in the probiotic phase compared to 
baseline (p = 0.006), however the differences between placebo and probiotic were not 
significant.  
 
Rapid visual information processing (RVP)  
The total correct hits increased following treatment with placebo and probiotic (p = < 
0.001) (Figure 4F), but there was no overall effect in the total false alarms (p = 0.53) 
(Figure 4F), or the reaction time (p = 0.48) (Figure 4H). 
 
Emotional Stroop 
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There was an increase in the percentage of correctly identified neutral words in the 
probiotic phase of treatment (p = 0.03) (Figure 4I), but this was not significantly 
greater than baseline (p = 0.54). There was no difference in reaction time to identify 
neutral words (p = 0.85) (Figure J). There were no significant differences in positive 
percent correct, positive reaction time, negative percent correct, negative reaction 
time (data not shown).  
 
Emotion Recognition task 
The total correctly identified emotions increased in the placebo and probiotic phase 
compared to baseline (p = < 0.001) (Figure 4K), manifest in the disgust (p = 0.02) and 
fear (p = < 0.001) categories, but no differences between placebo and probiotic. In 
addition, there was a non-significant decrease in time taken to correctly identify 
emotions in the placebo and probiotic phases (Figure 4L).  See Supplementary Table 4 
for pairwise comparisons.   
 
EEG 
There was a significant difference between placebo and probiotic for F3 zero crossings 
(second derivative) (p = 0.015), however, there was no significant difference in this 
index between baseline and placebo (p = 0.693) or between baseline and probiotic (p 
= 0.058). There were no significant differences between placebo and probiotic in any 
of the other measures. See Supplementary Table 5 for pairwise comparisons.   
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Discussion 
Preclinical data strongly supports the view that L. rhamnosus (JB-1) treatment has the 
capacity to alter central GABA transmission by acting through the vagus nerve (Bravo 
et al., 2011) and in so doing impact significantly on stress responses and behaviour. In 
this translational study conducted in healthy volunteers we failed to replicate the 
preclinical findings, which were conducted in an anxious mouse strain. In contrast to 
the preclinical data, this cross-over study found that L. rhamnosus treatment was not 
superior to placebo in improving cognitive performance and did not attenuate 
reported stress in healthy male subjects. Furthermore, probiotic treatment did not 
have a clear anti-inflammatory effect and did not attenuate the subjective stress 
response or HPA axis response during an acute stress procedure. This study highlights 
the challenges in translating the findings from candidate psychobiotics in stress-
susceptible animals, to healthy human populations. 
 
The candidate psychobiotic used in this study displayed a strong behavioural signal 
across multiple aspect of behaviour in well-validated screening assays in an anxious 
mouse strain (Bravo et al., 2011). However, over the eight week period of this trial, 
self-reported mood, anxiety, stress and sleep were constant and not significantly 
altered from baseline during the placebo or probiotic phases (Figure 1A-H). The data 
from other studies is mixed. For example, our results are consistent with a study by 
(Benton et al., 2007), albeit in an older age group, that showed no overall effect of 
Lactobacillus casei Shirota on mood and only a small improvement when post-hoc 
analysis of the lowest tertile mood scores were considered. After a 6 week, 
randomized, double-blind, placebo-controlled trial in petrochemical workers, there 
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was a significant improvement in the general health questionnaire score in the 
probiotic yogurt group (L. acidophilus LA5 and B. lactis BB12) and in the probiotic 
capsule group (L. casei, L. acidophilus, L. rhamnosus, L. bulgaricus, B. breve, B. longum, 
S. thermophiles), as well as a significant improvement in the depression anxiety and 
stress scale score in the probiotic yogurt and the multispecies probiotic capsule group. 
The improvement in scores in these scales were not seen in the conventional yogurt 
group (containing the starter cultures of S.thermophilus and L. bulgaricus). Probiotic 
treatment did not alter HPA axis function or the kynurenine/tryptophan ratio 
(Mohammadi et al., 2015b). The same group did not observe a significant effect 
between the groups in oxidative stress markers (Mohammadi et al., 2015a).   
 
A more recent study, that used a multi-species probiotic (B. bifidum W23, B. lactis 
W52, L. acidophilus W37, L. brevis W63, L. casei W56, L. salivarius W24, and 
Lactococcus lactis (W19 and W58), did not find significant changes in mood or anxiety 
as measured by the Beck Depression Inventory or Beck Anxiety Inventory, but 
reported a reduction on subscales of the Leiden index of depression for rumination 
and aggressive thoughts (Steenbergen et al., 2015). Another study in healthy controls, 
using L. helveticus R0052 and B. Longum R0175 found no change in stress, as 
measured by the perceived stress scale, but did report a reduction in anxiety scores 
using the Hospital Anxiety and Depression Scale and a reduction in the global severity 
index, somatisation, depression and anger–hostility scores in the Hopkins Symptoms 
Checklist (HSCL-90) (Messaoudi et al., 2011). Interestingly, we have recently shown 
that treatment with B. Longum resulted in an improvement in stress related behaviour 
and cognition in BALB/c mice (Savignac et al., 2014; Savignac et al., 2015) and this 
  
Kelly et al. L. rhamnosus (JB-1) A potential Psychobiotic 
 
18 
 
probiotic treatment modulated behaviour and stress responses in healthy male 
volunteers (Allen et al., 2016).  
 
From a physiological perspective, L. rhamnosus (JB-1) treatment also exhibited the 
capacity to reduce acute stress responses in mice (Bravo et al., 2011). Our participants 
exhibited an increased cortisol output in response to the acute stressor (Figure 2I). 
However, probiotic treatment did not attenuate cortisol output and there were no 
differences in subjective stress reports (Figure A-H). Although not utilizing an acute 
stress procedure, Messaoudi and colleagues found a significant difference in urinary 
cortisol levels between the L. helveticus R0052 and B. longum R0175 group and 
placebo groups (Messaoudi et al., 2011). In a study administering a prebiotic 
(galactooligosaccharide) to healthy controls for three weeks a significant decrease in 
the salivary cortisol awakening response compared to placebo was found (Schmidt et 
al., 2015).  
 
Our results suggest that L. rhamnosus (JB-1) treatment doesn’t affect either basal or 
stimulated immune responses. In contrast to our findings, both preclinical and clinical 
studies have previously shown that L. rhamnosus treatment has anti-inflammatory 
effects (Forsythe et al., 2012; Mortaz et al., 2015; Pessi et al., 2000). Thus, two key 
pillars of brain-gut axis signalling were not modified following psychobiotic treatment. 
In terms of cognition, the parallel mode of the PAL test (which presents different 
shapes at each visit) was used in order to avoid practice effects, and to assess 
conditional learning of pattern-location associations. PAL test performance is 
dependent upon the hippocampus (de Rover et al., 2011; Eichenbaum and Bunsey, 
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1995), which has a high proportion of glucocorticoid receptors (McEwen, 1999). A 
deficit in visuospatial memory performance, evident in PAL test performance, has 
been demonstrated in stress-related brain-gut axis disorders with a cognitive 
component such as IBS (Kennedy et al., 2015; Kennedy et al., 2014a). In this study, 
probiotic treatment was not superior to placebo across multiple cognitive domains 
including memory, attention, executive function and emotion recognition. Similarly, 
there were no significant differences of relevance in EEG measures between the 
probiotic treatment and the placebo.  
 
We employed a rigorous cross-over trial with a repeated measures design to control 
for potential effects of individual differences. Given that our study consisted of young 
healthy males, with normal mood, stress and anxiety scores and no deficits in HPA, 
inflammatory or cognitive function, demonstrating a clear probiotic effect over 
placebo in this population may be challenging. This inability to demonstrate 
superiority of treatment over placebo is not unusual, either in the assessment of 
psychotropics in general or in microbiota-directed interventions. For example, a novel 
and initially promising spore based microbiome therapy (SER-109) in Clostridium 
difficile infection (Khanna et al., 2016), was shown not to be statistically superior to 
placebo in a larger phase II trial (Seres, 2016). At each study visit, participants were 
asked whether they experienced any side effects from consumption of the capsules. 
Side effects were negligible, however, formal assessment of gastrointestinal function, 
was not carried out and is thus a limitation of the study. 
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There is an important difference in vulnerability between the anxious mouse strain 
used in the preclinical study and the healthy human volunteers that make up the 
clinical sample. It is worth noting in this regard that psychobiotics may be of limited 
benefit in healthy populations. Comparably, antidepressants also have a limited 
beneficial effect in healthy controls (Serretti et al., 2010). Moreover, antidepressants 
have a delayed onset of action (Taylor et al., 2006) and we acknowledge that more 
than four weeks of psychobiotic treatment may be required in future studies in 
populations with stress-related psychiatric disorders. A recent systematic review 
indicated that the impact of probiotic supplementation on gut microbiota structure, 
including an assessment across features such as α-diversity, richness and evenness, in 
healthy controls was minimal (Kristensen et al., 2016). However, it is important to 
consider that probiotic treatment may impact the function of colonizing microbes or 
promote homeostasis of the gut microbiota, rather than change its composition 
(Sanders, 2016).  
 
A more defined role for probiotic intervention may be in populations with some 
degree of pathology, for example IBS (Didari et al., 2015). Recently, several studies 
have demonstrated altered gut microbiota composition in depression (Jiang et al., 
2015; Kelly et al., 2016a; Naseribafrouei et al., 2014) and suggest that this altered gut 
microbiota composition may play a causal role in the development of certain features 
of depression (Kelly et al., 2016a; Zheng et al., 2016), though the precise mechanisms 
have yet to be elucidated. To date, only one small study has investigated a probiotic 
intervention in depressed patients (Akkasheh et al., 2016). In this eight week study, 
treatment with a multispecies probiotic containing L. acidophilus, L. casei and B. 
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bifidum, reportedly reduced depressive symptoms in moderately depressed patients 
compared to placebo.  
 
Despite the momentum provided by preclinical microbiome studies, there is a growing 
appreciation of the challenges in moving this work from bench to bedside (Arrieta et 
al., 2016; Dinan and Cryan, 2016). This includes the fact that the rodent 
gastrointestinal tract and microbiota composition differs from the human equivalent 
(Nguyen et al., 2015). It is worth noting that the effects of L. rhamnosus treatment 
were dependent on the vagus nerve (Bravo et al., 2011). The precise mediators 
between the gut microbiota and the vagus nerve have not been defined and could not 
therefore be assessed in this study. Moreover, it is important to note that the 
preclinical analysis of L. rhamnosus was carried out in BALB/c mice which are innately 
anxious and have different brain and gut responses to stress  
(Browne et al., 2011; Julio-Pieper et al., 2012; O'Mahony et al., 2010; Savignac et al., 
2011).  
 
Moreover, Bercik and colleagues have shown alterations in microbiota composition in 
this strain compared with strains with normal stress responses. Further, when these 
mice were transplanted with microbiota from a normo-anxious mouse their behaviour 
normalised suggesting a connection between host microbiota and behaviour (Collins 
et al., 2013). Recently, B. longum 1714, an alternative candidate psychobiotic selected 
following a similar preclinical screening battery in BALB/c mice, has been reported to 
reduce stress and improve memory (Allen et al., 2016), although a detailed 
mechanistic understanding of its effects in this regard is currently lacking. These 
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diverging outcomes highlight the issue of different putative psychobiotics likely 
exhibiting different mechanisms of action. Ultimately, this study, together with the 
SER-109 study illustrate the need to better understand the mechanisms, for effective 
translation. Whether the JB-1 strain has potential in the treatment of stress-related 
psychiatric disorders, either as a single agent, or in combination with other potential 
psychobiotics, remains an open question and further investigations are warranted. 
 
Conclusions 
This eight week randomized cross-over trial did not show that L. rhamnosus (JB-1) was 
superior to placebo in modifying stress-related measures, HPA responses, 
inflammation or cognitive performance in healthy male participants. These results 
suggest that some caution is required regarding expectations of targeting the gut 
microbiome in healthy populations and that there may be challenges in translating 
candidate psychobiotics with promising preclinical signals in anxious mouse strains 
into healthy human subjects. Future interventional studies investigating the effect of 
this probiotic in populations with stress-related disorders are required. 
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Figure Legends 
Figure 1: Subjective Stress Measures 
There was no overall effect of treatment phase in the (A) Beck Depression Inventory (p 
= 0.75), (B) the Beck Anxiety Inventory (p = 0.95), (C) the Perceived Stress Scale (p = 
0.053) (D), the State Anxiety Inventory (p = 0.09), (E) the Trait Anxiety Inventory (p = 
0.72), (F) the Symptom Checklist-90 (p = 0.87) or (G) the Pittsburgh sleep quality index 
(p = 0.07). (H) In the coping checklist, there was a reduction in wishful thinking (p = 
0.03) in the placebo (p = 0.04) and probiotic phase (p = 0.02).  
 
Figure 2: Acute Stress response to the Socially Evaluated Cold Pressor Test (SECPT) 
In the primary appraisal/secondary appraisal scale, there was no significant effect of 
probiotic the (A) primary appraisal (p = 0.73), (B) secondary appraisal (p = 0.14) in (C) 
control expectancy (p = 0.16), (D) self-control (p = 0.12), (E) threat (p = 0.27), (F) 
challenge (p = 0.51), (G) or stress index (p = 0.35). (H) There was no significant effect of 
treatment in pre-stress (p = 0.09), post-stress, (p = 0.51), difficulty (p = 0.29), 
unpleasantness (p = 0.12), or pain reports (p = 0.28). (I) There were no significant 
differences in the HPA response to the SECPT (p = 0.54), the (J) Area under the curve 
with respect to ground (AUCg) (p = 0.35) or the (K) delta cortisol response (p = 0.28). 
 
Figure 3: Immune response 
There was no overall treatment effect on the concentrations of (A) IL10 (p = 0.32) (B) 
IL1β = (p = 0.23), (C) IL6 (p = 0.13) or (D) IL8 (p = 0.16). (E) The concentration of TNFα 
increased from baseline during the placebo phase (p = 0.02), but there was no 
significant change in baseline versus probiotic (p = 0.08) or placebo versus probiotic (p 
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= 0.18). There was no overall treatment effect on the (F) IL1β:IL10 (p = 0.99), (G) 
IL6:IL10 (p = 0.12) (H) IL8:IL10 (p = 0.97), or (I) TNFα:IL10 (p = 0.99) ratios. Pairwise 
comparisons showed that the probiotic decreased the IL6:IL10 ratio (p = 0.03), though 
not significantly over placebo (p = 0.13). In the Toll-like 4 stimulated cytokines, there 
was an increase in the level of (J) IL1β (p = 0.02) and (K) TNFα (p = 0.01) during the 
placebo phase compared to baseline (p = 0.01). There was no effect of either 
treatment phase on (L) IL10 (p = 0.12) (M) IL6 (p = 0.22) or (N) IL8 (p = 0.25) cytokine 
release. 
 
Figure 4: Cognitive Measures  
In the paired associates learning task, there was no overall treatment effect on the (A) 
total errors made (p = 0.06), however at the (B) 8 shape stage, there was a significant 
reduction in errors from baseline in the placebo (p = 0.04) and probiotic group (p = 
0.04), but no significant difference between the placebo and probiotic. There was no 
significant difference in the (C) mean trials to success (p = 0.13). (D) In the attention 
switching task, there was an increase in the correct response in the placebo (p = 0.03) 
and probiotic phases (p = 0.01) compared to baseline, and a decrease in the (E) 
reaction time to correct response in the probiotic phase compared to baseline (p = 
0.006), however the differences between placebo and probiotic were not significant. 
In the rapid visual information processing task, the placebo and probiotic improved 
the (F) total correct hits (p = < 0.001), but there was no overall effect in the (G) total 
false alarms (p = 0.53) or the (H) reaction time (p = 0.48). In the emotional stroop task 
there was an increase in the percentage of correctly identified neutral words in the 
probiotic phase of treatment (I) (p = 0.03), but this was not significantly greater than 
  
Kelly et al. L. rhamnosus (JB-1) A potential Psychobiotic 
 
32 
 
baseline (p = 0.54). There was no difference in (J) reaction time to identify neutral 
words (p = 0.85). In the emotion recognition task, the (K) total correctly identified 
emotions increased in the placebo and probiotic phase compared to baseline (p = < 
0.001), manifest in the disgust (p = 0.02) and fear (p = < 0.001) emotion sub-
categories. (L) In addition, there was a non-significant decrease in time taken to 
correctly identify emotions in the placebo and probiotic phases.  
 
Table 1: Participant characteristics. Mean values (standard errors of the mean in 
parentheses). We assessed diet using a modified version of the food frequency 
questionnaire (Harrington et al., 2010) and presented the data in daily grams in 
Supplementary Table 6.  
Participant characteristics Total sample 
(n=29) 
Placebo / Probiotic  
(n=15) 
Probiotic / placebo 
(n=14) 
p-value 
Age (mean) 24.59 (0.75) 23.6 (0.97) 25.64 (1.14) 0.22 
Ethnicity         
Caucasian 25 13 12   
Asian 4 2 2 1.00 
BMI 24.55 (0.58) 24.8 (0.69) 24.29 (0.96) 0.66 
Alcohol (units per week) 10.14 (1.85) 11.85 (2.68) 8.42 (2.56) 0.36 
Years of Education 18.45 (0.49) 17.87 (0.71) 19.07 (0.65) 0.22 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4: Cognitive Measures 
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Research highlights 
• Lactobacillus rhamnosus (JB-1) has been shown to reduce stress-related behaviour, corticosterone release and alter central expression 
of GABA receptors in mice. 
• An 8 week, randomized, placebo-controlled, cross-over design trial was employed to assess the impact of L. rhamnosus on stress-related 
behaviours, physiology, inflammatory response, cognitive performance and brain activity patterns in 29 healthy male participants. 
• L. rhamnosus was not superior to placebo in modifying stress-related measures, HPA response, inflammation or cognitive performance.  
• These findings highlight the challenges associated with moving promising preclinical studies from bench to bedside. 
 
 
